How do I find out if I qualify for a diffuse midline glioma, h3 k27m-mutant study in Michigan?

Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.

Do I have to live in Michigan to take part?

Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.

Does it cost anything to join a diffuse midline glioma, h3 k27m-mutant trial?

Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.

Clinical trials · Michigan

Diffuse Midline Glioma, H3 K27M-Mutant clinical trials in Michigan

We’re tracking 4 recruiting diffuse midline glioma, h3 k27m-mutant studies with a site in Michigan — including Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.

Recruiting studies in Michigan

NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Ann Arbor, MichiganAges 2–39
NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Ann Arbor, MichiganAges 1–39
NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Ann Arbor, MichiganAges 1–39
NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Ann Arbor, MichiganAges 1–21

Diffuse Midline Glioma, H3 K27M-Mutant trials by city in Michigan

Detroit

Where these studies are running in Michigan

Institutions with a site for the recruiting diffuse midline glioma, h3 k27m-mutant studies listed above.

University of Michigan · 4 studies
Children's Hospital of Michigan
Corewell Health Grand Rapids Hospitals - Butterworth Hospital

What taking part in a diffuse midline glioma, h3 k27m-mutant study involves

A screening visit first

Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.

Care at a nearby site

Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.

You stay in control

Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.

The team decides eligibility

Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.

Diffuse Midline Glioma, H3 K27M-Mutant trials in other states

Common questions

Are there diffuse midline glioma, h3 k27m-mutant clinical trials in Michigan?: Yes. We're currently tracking 4 recruiting diffuse midline glioma, h3 k27m-mutant studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
How do I find out if I qualify for a diffuse midline glioma, h3 k27m-mutant study in Michigan?: Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
Do I have to live in Michigan to take part?: Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
Does it cost anything to join a diffuse midline glioma, h3 k27m-mutant trial?: Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.

Not the right time?

New diffuse midline glioma, h3 k27m-mutant studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.

Get told when a study that fits you opens

Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.